Drug Facts
Composition & Profile
Identifiers & Packaging
HOW SUPPLIED Each 50 mL of Clindamycin Injection USP in 5% Dextrose contains Clindamycin phosphate, USP equivalent to 300 mg, 600 mg, or 900 mg clindamycin; 2.5 g dextrose hydrous, USP; 2 mg edetate disodium dihydrate, USP; and Water for Injection, USP. pH may have been adjusted with sodium hydroxide and/or hydrochloric acid. The single dose GALAXY containers are available as follows: Code Product Description NDC Number 2G3466 Supplied as 24 bags per case 600 mg per 50 mL NDC 43066-993-24 2G3467 Supplied as 24 bags per case 900 mg per 50 mL NDC 43066-995-24 Exposure of pharmaceutical products to heat should be minimized. It is recommended that GALAXY plastic containers be stored at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid temperatures above 30°C.; PACKAGE/LABEL PRINCIPAL DISPLAY PANEL Container Label NDC 43066-993-24 Clindamycin Injection USP in 5% Dextrose 600 mg per 50 mL (12 mg / mL) Code 2G3466 Sterile Nonpyrogenic GALAXY 50 mL Single Dose Container Discard unused portion For Intravenous Use. Not for rapid injection or Intravenous push. Each 50 mL contains: Clindamycin phosphate, USP equivalent to 600 mg clindamycin, 2.5 g dextrose hydrous, USP, 2 mg edetate disodium dihydrate, USP, and Water for Injection, USP. pH may have been adjusted with sodium hydroxide and/or hydrochloric acid. Dosage: See prescribing information. Cautions: Do not add supplementary medication. Must not be used in series connections. Check for minute leaks and solution clarity. Rx only Store at 20°C to 25°C (68° to 77°F)[see USP Controlled Room Temperature]. Avoid temperatures above 30°C. novaplus Logo Galaxy is a registered trademark of Baxter International Inc. Novaplus is a registered trademark of Vizient, Inc. Manufactured by Baxter Healthcare Corporation , Deerfield, IL 60015 USA Made in USA 07-34-00-2150 BAR CODE POSITION ONLY 343066993245 Carton Label GALAXY Container novaplus Logo Galaxy is registered trademark of Baxter International Inc. Novaplus is registered trademark of Vizient Inc. Manufactured by Baxter Healthcare Corporation , Deerfield, IL 60015 Made in USA 07-04-00-1230 Clindamycin Injection USP in 5% Dextrose 600 mg per 50 mL (12 mg / mL) Contains 12 - 50 mL Single Dose Containers Store at 20° to 25°C (68° to 77°F)[see USP Controlled Room Temperature]. Avoid temperatures above 30°C. Rx only NDC 43066-993-24 Code 2G3466 *FOR BAR CODE POSITION ONLY (01) 20343066993249 For Intravenous Use. Not for rapid injection or Intravenous push. Sterile Nonpyrogenic Each 50 mL contains: Clindamycin phosphate, USP equivalent to 600 mg clindamycin, 2.5 g dextrose hydrous, USP, 2 mg edetate disodium dihydrate, USP, and Water for Injection, USP. pH may have been adjusted with sodium hydroxide and/or hydrochloric acid. Dosage: See prescribing information. Cautions: Do not add supplementary medication. Must not be used in series connections. Check for minute leaks and solution clarity. Container Label NDC 43066-995-24 Clindamycin Injection USP In 5% Dextrose 900 mg per 50 mL (18 mg / mL) Code 2G3467 Sterile Nonpyrogenic GALAXY 50 mL Single Dose Container Discard unused portion For Intravenous Use. Not for rapid injection or Intravenous push. Each 50 mL contains: Clindamycin phosphate, USP equivalent to 900 mg clindamycin, 2.5 g dextrose hydrous, USP, 2 mg edetate disodium dihydrate, USP, and Water for Injection, USP. pH may have been adjusted with sodium hydroxide and/or hydrochloric acid. Dosage: See prescribing information. Cautions: Do not add supplementary medication. Must not be used in series connections. Check for minute leaks and solution clarity. Rx only Store at 20°C to 25°C (68° to 77°F)[see USP Controlled Room Temperature]. Avoid temperatures above 30°C. novaplus Logo Galaxy is registered trademark of Baxter International Inc. Novaplus is a registered trademark of Vizient, Inc. Manufactured by Baxter Healthcare Corporation , Deerfield, IL 60015 USA Made in USA 07-34-00-2151 BAR CODE POSITION ONLY 343066995249 Carton Label GALAXY Container novaplus Logo Galaxy is registered trademark of Baxter International Inc. Novaplus is registered trademark of Vizient Inc. Manufactured by Baxter Healthcare Corporation , Deerfield, IL 60015 Made in USA 07-04-00-1231 Clindamycin Injection USP in 5% Dextrose 900 mg per 50 mL (18 mg / mL) Contains 12 - 50 mL Single Dose Containers Store at 20° to 25°C (68° to 77°F)[see USP Controlled Room Temperature]. Avoid temperatures above 30°C. Rx only NDC 43066-995-24 Code 2G3467 *FOR BAR CODE POSITION ONLY (01) 20343066995243 For Intravenous Use. Not for rapid injection or Intravenous push. Sterile Nonpyrogenic Each 50 mL contains: Clindamycin phosphate, USP equivalent to 900 mg clindamycin, 2.5 g dextrose hydrous, USP, 2 mg edetate disodium dihydrate, USP, and Water for Injection, USP. pH may have been adjusted with sodium hydroxide and/or hydrochloric acid. Dosage: See prescribing information. Cautions: Do not add supplementary medication. Must not be used in series connections. Check for minute leaks and solution clarity. Representative Container lbl 43066-993-24 1-2 Representative Container lbl 43066-993-24 2-2 Representative Carton lbl 43066-993-24 1-2 Representative Carton lbl 43066-993-24 2-2 Representative Container lbl 43066-995-24 1-2 Representative Container lbl 43066-995-24 2-2 Representative Carton lbl 43066-995-24 1-2 Representative Carton lbl 43066-995-24 2-2
- HOW SUPPLIED Each 50 mL of Clindamycin Injection USP in 5% Dextrose contains Clindamycin phosphate, USP equivalent to 300 mg, 600 mg, or 900 mg clindamycin; 2.5 g dextrose hydrous, USP; 2 mg edetate disodium dihydrate, USP; and Water for Injection, USP. pH may have been adjusted with sodium hydroxide and/or hydrochloric acid. The single dose GALAXY containers are available as follows: Code Product Description NDC Number 2G3466 Supplied as 24 bags per case 600 mg per 50 mL NDC 43066-993-24 2G3467 Supplied as 24 bags per case 900 mg per 50 mL NDC 43066-995-24 Exposure of pharmaceutical products to heat should be minimized. It is recommended that GALAXY plastic containers be stored at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid temperatures above 30°C.
- PACKAGE/LABEL PRINCIPAL DISPLAY PANEL Container Label NDC 43066-993-24 Clindamycin Injection USP in 5% Dextrose 600 mg per 50 mL (12 mg / mL) Code 2G3466 Sterile Nonpyrogenic GALAXY 50 mL Single Dose Container Discard unused portion For Intravenous Use. Not for rapid injection or Intravenous push. Each 50 mL contains: Clindamycin phosphate, USP equivalent to 600 mg clindamycin, 2.5 g dextrose hydrous, USP, 2 mg edetate disodium dihydrate, USP, and Water for Injection, USP. pH may have been adjusted with sodium hydroxide and/or hydrochloric acid. Dosage: See prescribing information. Cautions: Do not add supplementary medication. Must not be used in series connections. Check for minute leaks and solution clarity. Rx only Store at 20°C to 25°C (68° to 77°F)[see USP Controlled Room Temperature]. Avoid temperatures above 30°C. novaplus Logo Galaxy is a registered trademark of Baxter International Inc. Novaplus is a registered trademark of Vizient, Inc. Manufactured by Baxter Healthcare Corporation , Deerfield, IL 60015 USA Made in USA 07-34-00-2150 BAR CODE POSITION ONLY 343066993245 Carton Label GALAXY Container novaplus Logo Galaxy is registered trademark of Baxter International Inc. Novaplus is registered trademark of Vizient Inc. Manufactured by Baxter Healthcare Corporation , Deerfield, IL 60015 Made in USA 07-04-00-1230 Clindamycin Injection USP in 5% Dextrose 600 mg per 50 mL (12 mg / mL) Contains 12 - 50 mL Single Dose Containers Store at 20° to 25°C (68° to 77°F)[see USP Controlled Room Temperature]. Avoid temperatures above 30°C. Rx only NDC 43066-993-24 Code 2G3466 *FOR BAR CODE POSITION ONLY (01) 20343066993249 For Intravenous Use. Not for rapid injection or Intravenous push. Sterile Nonpyrogenic Each 50 mL contains: Clindamycin phosphate, USP equivalent to 600 mg clindamycin, 2.5 g dextrose hydrous, USP, 2 mg edetate disodium dihydrate, USP, and Water for Injection, USP. pH may have been adjusted with sodium hydroxide and/or hydrochloric acid. Dosage: See prescribing information. Cautions: Do not add supplementary medication. Must not be used in series connections. Check for minute leaks and solution clarity. Container Label NDC 43066-995-24 Clindamycin Injection USP In 5% Dextrose 900 mg per 50 mL (18 mg / mL) Code 2G3467 Sterile Nonpyrogenic GALAXY 50 mL Single Dose Container Discard unused portion For Intravenous Use. Not for rapid injection or Intravenous push. Each 50 mL contains: Clindamycin phosphate, USP equivalent to 900 mg clindamycin, 2.5 g dextrose hydrous, USP, 2 mg edetate disodium dihydrate, USP, and Water for Injection, USP. pH may have been adjusted with sodium hydroxide and/or hydrochloric acid. Dosage: See prescribing information. Cautions: Do not add supplementary medication. Must not be used in series connections. Check for minute leaks and solution clarity. Rx only Store at 20°C to 25°C (68° to 77°F)[see USP Controlled Room Temperature]. Avoid temperatures above 30°C. novaplus Logo Galaxy is registered trademark of Baxter International Inc. Novaplus is a registered trademark of Vizient, Inc. Manufactured by Baxter Healthcare Corporation , Deerfield, IL 60015 USA Made in USA 07-34-00-2151 BAR CODE POSITION ONLY 343066995249 Carton Label GALAXY Container novaplus Logo Galaxy is registered trademark of Baxter International Inc. Novaplus is registered trademark of Vizient Inc. Manufactured by Baxter Healthcare Corporation , Deerfield, IL 60015 Made in USA 07-04-00-1231 Clindamycin Injection USP in 5% Dextrose 900 mg per 50 mL (18 mg / mL) Contains 12 - 50 mL Single Dose Containers Store at 20° to 25°C (68° to 77°F)[see USP Controlled Room Temperature]. Avoid temperatures above 30°C. Rx only NDC 43066-995-24 Code 2G3467 *FOR BAR CODE POSITION ONLY (01) 20343066995243 For Intravenous Use. Not for rapid injection or Intravenous push. Sterile Nonpyrogenic Each 50 mL contains: Clindamycin phosphate, USP equivalent to 900 mg clindamycin, 2.5 g dextrose hydrous, USP, 2 mg edetate disodium dihydrate, USP, and Water for Injection, USP. pH may have been adjusted with sodium hydroxide and/or hydrochloric acid. Dosage: See prescribing information. Cautions: Do not add supplementary medication. Must not be used in series connections. Check for minute leaks and solution clarity. Representative Container lbl 43066-993-24 1-2 Representative Container lbl 43066-993-24 2-2 Representative Carton lbl 43066-993-24 1-2 Representative Carton lbl 43066-993-24 2-2 Representative Container lbl 43066-995-24 1-2 Representative Container lbl 43066-995-24 2-2 Representative Carton lbl 43066-995-24 1-2 Representative Carton lbl 43066-995-24 2-2
Overview
Clindamycin Injection USP in 5% Dextrose in the GALAXY plastic container for intravenous use is composed of clindamycin phosphate equivalent to 300, 600 and 900 mg of clindamycin premixed with 5% dextrose as a sterile solution. Disodium edetate has been added at a concentration of 0.04 mg/mL. The pH has been adjusted with sodium hydroxide and/or hydrochloric acid. Clindamycin is a semisynthetic antibiotic produced by a 7(S)‑chloro-substitution of the 7(R)-hydroxyl group of the parent compound lincomycin. The chemical name of clindamycin phosphate is L- threo -α-D- galacto -Octopyranoside, methyl-7-chloro-6,7,8-trideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl]amino]‑1-thio-, 2-(dihydrogen phosphate), (2S- trans )-. The molecular formula is C 18 H 34 ClN 2 O 8 PS and the molecular weight is 504.96. The structural formula is represented below: Clindamycin Injection USP in 5% Dextrose in the GALAXY plastic containers is for Intravenous Use. The plastic container is fabricated from a specially designed multilayer plastic. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period. The suitability of the plastic has been confirmed in tests in animals according to the USP biological tests for plastic containers, as well as by tissue culture toxicity studies. Clindamycin in 5% Dextrose Structural Formula
Indications & Usage
Clindamycin Injection USP in 5% Dextrose products are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection USP in 5% Dextrose products are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection USP in 5% Dextrose is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae , other streptococci (except E. faecalis ), and Staphylococcus aureus . Skin and skin structure infections caused by Streptococcus pyogenes , Staphylococcus aureus , and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus , streptococci (except Enterococcus faecalis ), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Clindamycin Injection USP in 5% Dextrose and other antibacterial drugs, Clindamycin Injection USP in 5% Dextrose should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Dosage & Administration
If diarrhea occurs during therapy, this antibiotic should be discontinued (see WARNING box). Adults: Parenteral (IV Administration): Serious infections due to aerobic gram-positive cocci and the more susceptible anaerobes (NOT generally including Bacteroides fragilis , Peptococcus species and Clostridium species other than Clostridium perfringens ): 600-1200 mg/day in 2, 3 or 4 equal doses. More severe infections, particularly those due to proven or suspected Bacteroides fragilis, Peptococcus species, or Clostridium species other than Clostridium perfringens : 1200-2700 mg/day in 2, 3 or 4 equal doses. For more serious infections, these doses may have to be increased. In life-threatening situations due to either aerobes or anaerobes these doses may be increased. Doses of as much as 4800 mg daily have been given intravenously to adults. See Dilution for IV use and IV Infusion Rates section below. Alternatively, drug may be administered in the form of a single rapid infusion of the first dose followed by continuous IV infusion as follows: Table 2: Serum Clindamycin Levels Maintained, Rapid Infusion Rate and Maintenance Infusion Rate To maintain serum clindamycin levels Rapid infusion rate Maintenance infusion rate Above 4 mcg/mL 10 mg/min for 30 min 0.75 mg/min Above 5 mcg/mL 15 mg/min for 30 min 1.00 mg/min Above 6 mcg/mL 20 mg/min for 30 min 1.25 mg/min Pediatric patients 1 month of age to 16 years: Parenteral (IV) Administration: 20 to 40 mg/kg/day in 3 or 4 equal doses. The higher doses would be used for more severe infections. Clindamycin should be dosed based on total body weight regardless of obesity. As an alternative to dosing on a body weight basis, pediatric patients may be dosed on the basis of square meters body surface: 350 mg/m 2 /day for serious infections and 450 mg/m 2 /day for more severe infections. Parenteral therapy may be changed to oral clindamycin palmitate hydrochloride powder for oral solution or clindamycin hydrochloride capsules when the condition warrants and at the discretion of the physician. In cases of β-hemolytic streptococcal infections, treatment should be continued for at least 10 days. Pediatric Patients less than 1 month: The recommended dosage is 15 to 20 mg/kg/day in 3 to 4 equal doses. See Table 3 regarding the dosing regimen for pediatric patients with post-menstrual age (PMA) less than or equal to 32 weeks, or greater than 32 weeks to less than or equal to 40 weeks. Table 3: Dosing Regimens for Pediatric Patients with PMA less than or equal to 32 weeks, or greater than 32 weeks to less than or equal to 40 weeks PMA (weeks) Dose (mg/kg) Dosing Interval (hours) Less than or equal to 32 5 8 Greater than or equal to 32 to less than or equal to 40 7 8 PMA: Post-Menstrual Age Dilution for IV use and IV Infusion Rates The concentration of clindamycin in diluent for infusion should not exceed 18 mg per mL. Infusion rates should not exceed 30 mg per minute. The usual infusion dilutions and rates are as follows: Dose Diluent Time 300 mg 50 mL 10 min 600 mg 50 mL 20 min 900 mg 50–100 mL 30 min 1200 mg 100 mL 40 min Administration of more than 1200 mg in a single 1-hour infusion is not recommended. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Warnings & Precautions
WARNINGS See BOXED WARNING . Clostridioides difficile- Associated Diarrhea Clostridioides difficile- associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Clindamycin Injection USP in 5% Dextrose, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated. Anaphylactic and Severe Hypersensitivity Reactions Anaphylactic shock and anaphylactic reactions have been reported (see ADVERSE REACTIONS ). Severe hypersensitivity reactions, including severe skin reactions such as toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and Stevens-Johnson syndrome (SJS), some with fatal outcome, have been reported (see ADVERSE REACTIONS ). In case of such an anaphylactic or severe hypersensitivity reaction, discontinue treatment permanently and institute appropriate therapy. A careful inquiry should be made concerning previous sensitivities to drugs and other allergens. Nephrotoxicity Clindamycin is potentially nephrotoxic and cases with acute kidney injury have been reported. Consider monitoring of renal function particularly in patients with pre-existing renal dysfunction or those taking concomitant nephrotoxic drugs. In case of acute kidney injury, discontinue Clindamycin Injection USP in 5% Dextrose when no other etiology is identified. Usage in Meningitis- Since clindamycin does not diffuse adequately into the cerebrospinal fluid, the drug should not be used in the treatment of meningitis.
Boxed Warning
Clostridioides difficile -associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Clindamycin Injection USP in 5% Dextrose and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . Because Clindamycin Injection USP in 5% Dextrose therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the INDICATIONS AND USAGE section. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated.
Contraindications
This drug is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.
Adverse Reactions
The following reactions have been reported with the use of clindamycin. Infections and Infestations: Clostridioides difficile colitis Gastrointestinal: Antibiotic-associated colitis (see WARNINGS ), pseudomembranous colitis, abdominal pain, nausea, and vomiting. The onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment (see WARNINGS ). An unpleasant or metallic taste has been reported after intravenous administration of the higher doses of clindamycin phosphate. Hypersensitivity Reactions: Maculopapular rash and urticaria have been observed during drug therapy. Generalized mild to moderate morbilliform-like skin rashes are the most frequently reported of all adverse reactions. Severe skin reactions such as Toxic Epidermal Necrolysis, some with fatal outcome, have been reported (see WARNINGS ). Cases of Acute Generalized Exanthematous Pustulosis (AGEP), erythema multiforme, some resembling Stevens-Johnson syndrome, have been associated with clindamycin. Anaphylactic shock, anaphylactic reaction and hypersensitivity have also been reported (see WARNINGS ). Skin and Mucous Membranes: Pruritus, vaginitis, angioedema and rare instances of exfoliative dermatitis have been reported (see Hypersensitivity Reactions ). Liver: Jaundice and abnormalities in liver function tests have been observed during clindamycin therapy. Renal: Acute kidney injury (see WARNINGS ). Hematopoietic: Transient neutropenia (leukopenia) and eosinophilia have been reported. Reports of agranulocytosis and thrombocytopenia have been made. No direct etiologic relationship to concurrent clindamycin therapy could be made in any of the foregoing. Immune System: Drug reaction with eosinophilia and systemic symptoms (DRESS) cases have been reported. Local Reactions: Thrombophlebitis has been reported after intravenous infusion. Reactions can be minimized by avoiding prolonged use of indwelling intravenous catheters. Musculoskeletal: Polyarthritis cases have been reported. Cardiovascular: Cardiopulmonary arrest and hypotension have been reported following too rapid intravenous administration (see DOSAGE AND ADMINISTRATION ).
Drug Interactions
Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents. Clindamycin is metabolized predominantly by CYP3A4, and to a lesser extent by CYP3A5, to the major metabolite clindamycin sulfoxide and minor metabolite N‑desmethylclindamycin. Therefore, inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin. In the presence of strong CYP3A4 inhibitors, monitor for adverse reactions. In the presence of strong CYP3A4 inducers such as rifampicin, monitor for loss of effectiveness. In vitro studies indicate that clindamycin does not inhibit CYP1A2, CYP2C9, CYP2C19, CYP2E1 or CYP2D6 and only moderately inhibits CYP3A4.
Similar Drugs
Related medications based on brand, generic name, substance, active ingredients.